EOLS — Evolus, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1570562 ·
Last close
$6.69
Market Cap
$442.80M
52W High
$9.31
52W Low
$3.86
ADV30
974,315
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 77,952,000 50,686,000 -5,782,000 -12,516,000 283,823,000 41,700,000 321,637,000
Jun 2026 84,084,000 57,180,000 -3,293,000 -8,052,000 248,024,000 45,170,000 278,927,000
Mar 2026 73,137,000 48,897,000 -6,862,000 -10,674,000 220,646,000 49,792,000 249,427,000
Dec 2025 90,300,000 59,291,000 -291,000 130,000 225,868,000 53,826,000 248,974,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,645,000
Investing CF
$-6,171,000
Financing CF
$7,432,000
CapEx
$-6,171,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.47
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-692,282,000
Inventory
$82,804,000
Receivables
$60,280,000
ST Investments
—
EBIT TTM
$-13,968,000
Pretax Income TTM
$-30,340,000
Interest Exp TTM
$16,372,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$325,472,992
EBITDA
$-8,275,000
Free Cash Flow
$13,406,625
Enterprise Value
$573,982,080
Total Cash
$41,700,000
Total Debt
$165,584,992
Shares Out
66,188,366
Trailing EPS
$-0.48
Book Value
$-0.57
ROE
—
ROA
-4.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 297,176,000 -37,600,000 -51,641,000 225,868,000 248,974,000 -23,106,000 -42,265,000
Dec 2024 266,274,000 -27,235,000 -50,420,000 232,569,000 227,047,000 5,522,000 -17,999,000
Dec 2023 202,085,000 -44,976,000 -61,685,000 188,998,000 209,687,000 -20,689,000 -34,008,000
Dec 2022 148,616,000 -59,575,000 -74,412,000 177,983,000 159,484,000 18,499,000 -84,912,000

TTM Snapshot

Revenues TTM
$316,488,000
NetIncome TTM
$-34,333,000
OpCashFlow TTM
—
Assets (Latest)
$248,024,000
Forward EPS
$0.29

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.50 · spot: $7.07 · call volume: 33 · put volume: 13
Expected Move to 2027-01-15: ±$1.25 (17.68%) — implied range $5.82 – $8.32 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
INDP Indaptus Therapeutics, Inc. $442.36M $3.32 —
ARVN ARVINAS, INC. $446.61M $6.82 —
PHAT Phathom Pharmaceuticals, Inc. $447.10M $5.50 —
EPRX EUPRAXIA PHARMACEUTICALS INC. $437.41M $6.62 —
DMAC DiaMedica Therapeutics Inc. $452.16M $8.38 —

News headlines (Yahoo Finance, 1h cache)

Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows
2026-11-16 02:12 · Yahoo
Evolus (EOLS) Q3 2026 Earnings Call Transcript
2026-11-05 16:28 · Yahoo
Evolus, Inc. Q3 2026 Earnings Call Summary
2026-11-05 13:30 · Yahoo
Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive Adjusted ...
2026-11-05 13:09 · Yahoo
What Evolus (EOLS) Said on Its Q3 Earnings Call
2026-11-05 02:14 · Yahoo
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 23:45 · Yahoo
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlo
2026-11-04 21:05 · Yahoo
Evolus to Participate in Upcoming Investor Conferences in New York and London
2026-10-28 12:30 · Yahoo
Evolus to Report Third Quarter Financial Results on November 4, 2026
2026-10-21 12:30 · Yahoo
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
2026-10-14 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.